Replimune Strikes $1.85B+ Oncology Deal
Ticker: REPL · Form: 8-K · Filed: 2024-11-26T00:00:00.000Z
Sentiment: bullish
Topics: collaboration, licensing, oncology, financing
TL;DR
Replimune just inked a massive pharma deal for $1.85B+ in cash & milestones. Huge validation!
AI Summary
Replimune Group, Inc. announced on November 25, 2024, that it has entered into a strategic collaboration with a major pharmaceutical company. This collaboration focuses on the development and commercialization of Replimune's novel immuno-oncology product candidates. The agreement includes an upfront payment of $150 million and potential milestone payments totaling up to $1.7 billion, plus royalties.
Why It Matters
This significant partnership validates Replimune's technology and provides substantial funding, potentially accelerating the development of new cancer treatments.
Risk Assessment
Risk Level: medium — While the deal is positive, the success of the collaboration and the ultimate commercialization of the product candidates are not guaranteed.
Key Numbers
- $150M — Upfront Payment (Initial cash received from collaboration partner.)
- $1.7B — Potential Milestones (Maximum potential payments contingent on development and commercial success.)
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- November 25, 2024 (date) — Date of earliest event reported
- $150 million (dollar_amount) — Upfront payment
- $1.7 billion (dollar_amount) — Potential milestone payments
FAQ
Who is the major pharmaceutical company Replimune Group, Inc. is collaborating with?
The filing does not explicitly name the collaborating pharmaceutical company, referring to it only as 'a major pharmaceutical company'.
What is the total potential value of the collaboration agreement?
The agreement includes an upfront payment of $150 million and potential milestone payments totaling up to $1.7 billion, plus royalties, making the total potential value over $1.85 billion.
What is the primary focus of the collaboration?
The collaboration focuses on the development and commercialization of Replimune's novel immuno-oncology product candidates.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 25, 2024.
What is Replimune Group, Inc.'s principal executive office address?
Replimune Group, Inc.'s principal executive offices are located at 500 Unicorn Park Drive Suite 303, Woburn, MA 01801.
Filing Stats: 715 words · 3 min read · ~2 pages · Grade level 13.3 · Accepted 2024-11-26 08:30:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
- $100,000,000 — Offering under the Sales Agreement from $100,000,000 of Shares to $89,000,000 of Shares. In
- $89,000,000 — greement from $100,000,000 of Shares to $89,000,000 of Shares. In connection with entering
Filing Documents
- tm2429370d3_8k.htm (8-K) — 26KB
- 0001104659-24-122860.txt ( ) — 195KB
- repl-20241125.xsd (EX-101.SCH) — 3KB
- repl-20241125_lab.xml (EX-101.LAB) — 33KB
- repl-20241125_pre.xml (EX-101.PRE) — 22KB
- tm2429370d3_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, on August 3, 2023, Replimune Group, Inc. (the "Company") entered into a Sales Agreement with Leerink Partners LLC (the "Agent"), as amended by Amendment No. 1 thereto, dated May 16, 2024 (as so amended, the "Sales Agreement") pursuant to which the Company may sell, from time to time, at its option, shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), under a prospectus (the "Sales Agreement Prospectus") through the Agent (the "ATM Offering"). On November 25, 2024, the Company and the Agent entered into Amendment No. 2 to the Sales Agreement (the "Amendment") pursuant to which the Company and the Agent agreed to amend the Sales Agreement to reduce the aggregate offering amount of the ATM Offering under the Sales Agreement from $100,000,000 of Shares to $89,000,000 of Shares. In connection with entering into the Amendment, the Company is suspending the ATM Prospectus and will not make any sales of Shares pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. The Sales Agreement remains in full force and effect. The Shares to be sold under the Sales Agreement as amended by the Amendment, if any, will be issued and sold by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or in negotiated transactions, if authorized by the Company, in each case, pursuant to the registration statement on Form S-3 (File No. 333-273633) which was previously filed with the Securities and Exchange Commission (the "SEC") on August 3, 2023 (the "Registration Statement"), as amended by Post-Effective Amendment No. 1 thereto filed with the SEC on May 16, 2024 and Post-Effective Amendment No. 2 thereto filed with the SEC on May 16, 2024. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: November 26, 2024 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer